Catalent Acquires New Biologics Facility in Indiana

Catalent announced on Sept. 24, 2020 that it has acquired a manufacturing facility in Bloomington, IN to create a new North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services. The $14 million investment includes the acquisition, build-out, and qualification of the facility.

The 23,000 ft2 site, purchased from AB BioTechnologies and its affiliate, features a new Vanrx SA25 aseptic flexible filling line for the filling of lyophilized vials, syringes, and cartridges; formulation development capabilities; quality control laboratories; and controlled temperature storage, a company press release said. Set to be operational in January 2021, the facility will also be integrated with Catalent Biologics’ main Bloomington facility located nearby.

“The addition of this new small-scale filling capability underlines Catalent’s commitment to our customers with early stage programs looking to accelerate molecules into the clinic,” said Mike Riley, Catalent’s region president, Biologics, North America, in the press release. “The filling line will also be fully leveraged as part of our OneBio offering, an integrated solution for drug substance and drug product development, manufacturing, and clinical supply, enabling faster development timelines to Phase 1 clinical trials and beyond.”